Hormonal IUD (Mirena/Kyleena) and Finasteride: What Women Need to Know

Does Using a Hormonal IUD With Finasteride Cause a Drug Interaction?

There is no pharmacokinetic drug interaction between levonorgestrel (the hormone in Mirena and Kyleena) and finasteride. The two drugs do not compete for the same metabolic enzymes in a way that raises or lowers each other's blood levels in a clinically important way. The interaction that does exist is pharmacodynamic: both drugs work on the androgen pathway, and their combined effect on androgen activity is additive.

Understanding why requires a brief look at how each drug works.

How Levonorgestrel Works in the IUD

Levonorgestrel is a synthetic progestin with moderate androgenic activity. In the 52-mg Mirena IUD, systemic serum levonorgestrel averages approximately 150 picograms per milliliter in the first year, falling to around 100 pg/mL by year five. Kyleena (19.5 mg) releases lower doses, averaging around 45 pg/mL. Because the IUD delivers most of its effect locally in the uterus, systemic progestogenic and androgenic effects are considerably smaller than those from oral progestins. Even so, levonorgestrel does bind to the androgen receptor, with roughly 40 to 45 percent of the relative binding affinity of testosterone at that receptor site.

How Finasteride Works

Finasteride inhibits 5-alpha reductase (5-AR) type II, the enzyme that converts testosterone into dihydrotestosterone (DHT). DHT is the more potent androgen responsible for hair follicle miniaturization, sebaceous gland stimulation, and other androgen-sensitive tissue effects. At the standard 1-mg dose for androgenic alopecia, finasteride reduces scalp DHT by approximately 64 percent and serum DHT by approximately 60 to 70 percent. At 5 mg (used off-label for hirsutism or PCOS), serum DHT suppression is deeper.

Where the Pathways Overlap

Levonorgestrel has the potential to be converted via 5-AR into a more active androgenic metabolite (5-alpha-dihydrolevonorgestrel). By inhibiting 5-AR, finasteride theoretically reduces this conversion. This means finasteride may actually blunt part of the androgenic signaling that levonorgestrel carries, which in theory could reduce any unwanted androgenic side effects from the IUD (such as acne or hair thinning that some women report with levonorgestrel-containing IUDs). This is a mechanistic inference, not a conclusion from a dedicated clinical trial.

The Evidence Gap Women Deserve to Know About

Direct clinical trial data on women using a levonorgestrel IUD alongside finasteride does not exist. This matters. Women have been systematically underrepresented in pharmacokinetic and drug-drug interaction studies, and reproductive-age women using contraception are almost always excluded from trials of drugs like finasteride because of its teratogenicity. What clinicians apply here is mechanistic reasoning layered on top of finasteride pharmacokinetic data and levonorgestrel pharmacokinetic data studied separately.

The WomanRx Androgen-Overlap Framework for this combination identifies three clinical scenarios where a prescriber needs to think through the interaction explicitly:

1. A woman with androgenic alopecia using Mirena for contraception who is starting finasteride 1 mg.
2. A woman with PCOS using the levonorgestrel IUD for cycle regulation and heavy bleeding who is starting finasteride 2.5 to 5 mg for hirsutism.
3. A perimenopausal woman using Mirena for endometrial protection during hormone therapy who is starting finasteride for late-onset androgenic alopecia.

Each scenario carries different baseline androgen levels, different expected pharmacodynamic overlap, and different monitoring priorities.

Pharmacokinetics: Why the IUD Route Matters

The route of levonorgestrel delivery is actually protective when thinking about systemic drug interactions. Because the IUD acts primarily at the uterine level, systemic levonorgestrel concentrations are low enough that competition for hepatic metabolism is unlikely to be clinically significant.

CYP Enzymes and Finasteride

Finasteride is metabolized primarily by CYP3A4. Levonorgestrel is also partially metabolized by CYP3A4, but because IUD-released levonorgestrel circulates at very low concentrations (45 to 150 pg/mL depending on device and time since insertion), competition at CYP3A4 is unlikely to meaningfully alter finasteride exposure.

Oral levonorgestrel in combination pills reaches serum concentrations roughly four to six times higher than IUD-delivered levonorgestrel. If you were taking finasteride with a levonorgestrel-containing combined oral contraceptive, the interaction picture would need more careful consideration. With an IUD, systemic concentrations are low enough that enzyme competition is not a practical concern.

P-glycoprotein

Neither finasteride nor levonorgestrel is a major P-glycoprotein substrate or inhibitor at therapeutic doses, so P-gp-mediated interactions are not a concern here.

Androgenic Side Effects: Does Finasteride Help or Hurt With an IUD?

Some women using Mirena notice new or worsened acne, increased facial or body hair, or scalp hair thinning. This is thought to reflect the weak androgenic activity of levonorgestrel at the androgen receptor. A 2020 analysis in the journal Contraception found that levonorgestrel IUD users reported androgenic side effects at rates between 3 and 8 percent depending on the study population.

Finasteride, by reducing DHT, may counteract some of this androgenic signaling. Women who are already on finasteride when they get a levonorgestrel IUD inserted may therefore experience fewer androgenic side effects from the IUD than women who are not. This is not a researched clinical benefit. It is a mechanistic inference that needs a prospective study before anyone should rely on it as a treatment strategy.

The reverse question, whether combined androgen suppression could cause symptoms of androgen deficiency (fatigue, low libido, mood changes), deserves attention too. Women with baseline low androgens, particularly those who are perimenopausal, may be more sensitive to additive androgen-lowering effects.

Who Is Most Likely to Use Both of These Drugs?

Women With PCOS

PCOS affects approximately 8 to 13 percent of reproductive-age women worldwide, making it the most common endocrine disorder in this group. Many women with PCOS use a levonorgestrel IUD for cycle regulation and to protect the endometrium from hyperplasia. Finasteride at 2.5 to 5 mg is sometimes prescribed off-label for hirsutism and androgenic alopecia in PCOS, particularly when spironolactone is not tolerated or is contraindicated.

In this population, the pharmacodynamic overlap is intentional. The IUD manages the uterine consequences of unopposed estrogen; finasteride manages the peripheral androgen-driven symptoms. The combination makes clinical sense, though prescribers should monitor for over-suppression of androgens in women who already have low total testosterone.

Women With Androgenic Alopecia

Female pattern hair loss affects roughly 40 percent of women by age 50. Finasteride at 1 to 2.5 mg is used off-label (FDA has approved it at 1 mg for men only) in premenopausal women, always requiring reliable contraception given its teratogenicity. A levonorgestrel IUD provides that contraception while also offering cycle management. This is a common real-world pairing.

Perimenopausal Women

Mirena at 52 mg is widely used to provide the progestogenic component of menopausal hormone therapy, protecting the endometrium in women on estrogen. Androgenic alopecia often accelerates in perimenopause as estrogen declines. Some clinicians add finasteride in this setting. The endogenous androgen environment in perimenopause is already shifting, so monitoring total and free testosterone before and after starting finasteride is reasonable practice.

Pregnancy, Lactation, and Contraception: The Non-Negotiable Section

This section applies any time finasteride is prescribed to a woman of reproductive potential.

Finasteride Is Category X

The FDA label for finasteride states clearly that it is contraindicated in women who are or may become pregnant. Animal studies at doses producing fetal finasteride exposure equivalent to or lower than those expected from human therapeutic doses caused feminization of male rat fetuses, specifically hypospadias and other abnormalities of external genitalia. The drug crosses the placenta.

Category X means: the risks in pregnancy clearly outweigh any possible benefit. There is no safe dose in pregnancy.

What This Means for Contraception

Every woman of reproductive potential taking finasteride must use highly effective contraception. A levonorgestrel IUD, with a failure rate below 0.1 to 0.2 percent per year with perfect use, meets that standard. ACOG and the CDC U.S. Medical Eligibility Criteria classify intrauterine devices as the most effective reversible contraceptive methods available. This is actually one of the strongest clinical arguments for pairing finasteride with a hormonal IUD rather than a barrier method or lower-efficacy method.

If you stop the IUD while still taking finasteride, you must use an alternative highly effective method immediately. There is no "washout" grace period during which unprotected sex is acceptable while on finasteride.

How Long After Stopping Finasteride Is It Safe to Try to Conceive?

Finasteride has a half-life of five to six hours in premenopausal women (somewhat different from the eight-hour half-life described in older male studies). It is not stored in fatty tissue. Most pharmacokineticists consider systemic clearance essentially complete within two to three days of the last dose. A conservative recommendation from most reproductive endocrinologists is to wait at least one full menstrual cycle (approximately four weeks) after stopping finasteride before attempting conception. Some clinicians recommend three months to be cautious, though the pharmacokinetic data do not strictly require it.

Finasteride and Breastfeeding

There are no human data on finasteride transfer into breast milk. Animal studies suggest transfer does occur. The absence of human lactation data means finasteride is not recommended during breastfeeding. This is an area where the evidence gap is absolute.

The levonorgestrel IUD, by contrast, is compatible with breastfeeding. ACOG guidance supports IUD placement as early as 10 minutes after placental delivery or at the six-week postpartum visit. Small amounts of levonorgestrel transfer into breast milk but are not considered harmful to the infant at IUD doses.

Who This Combination Is Right For (and Who Should Reconsider)

Good Candidates

• Women with androgenic alopecia who want highly effective contraception while on finasteride.
• Women with PCOS who need both endometrial protection and treatment of peripheral androgen excess.
• Women approaching perimenopause who use Mirena as the progestogenic arm of HRT and develop scalp hair loss as androgen balance shifts.
• Women who cannot tolerate spironolactone (the most common alternative for androgen excess in women) due to side effects such as hyperkalemia or significant menstrual disruption.

Women Who Should Discuss Alternatives or Proceed Cautiously

• Women with very low baseline androgens (total testosterone below 15 ng/dL on testing) who may experience symptoms of androgen deficiency with additive suppression.
• Women with a history of significant mood changes on progestin-containing contraception, as the pharmacodynamic androgen overlap could contribute to mood effects.
• Women actively trying to conceive: finasteride is absolutely contraindicated, full stop, regardless of IUD use.
• Women in the postpartum period who are breastfeeding: the IUD is appropriate; finasteride is not.

Monitoring: What to Track and When

There is no formal monitoring protocol published for this specific combination because no guideline body has addressed it directly. Applying clinical reasoning from the individual drug labels and from androgen-management guidelines in PCOS and female-pattern hair loss, the following approach is reasonable.

Before Starting Finasteride (With IUD Already in Place)

Obtain a baseline androgen panel: total testosterone, free testosterone (by equilibrium dialysis where available), DHEAS, and sex hormone-binding globulin. This gives you a reference point for evaluating any future symptoms of over-suppression.

Confirm highly effective contraception is in place and that the IUD string check is current.

Review the menstrual pattern. Women using a levonorgestrel IUD often experience lighter periods or amenorrhea. This is expected and not a sign of pregnancy. Any break-through bleeding after finasteride is added is worth investigating but is more likely related to IUD effects than to the drug interaction.

Three to Six Months After Starting Finasteride

Reassess hair loss response and any androgenic side effects from the IUD (acne, hirsutism). Repeat androgen panel only if symptoms suggest over-suppression (fatigue, low libido, mood changes that are new).

Ongoing

Annual IUD string check per standard-of-care. Finasteride effect on hair loss takes at least six months to assess; most dermatologists and prescribers evaluate response at 12 months. The International Society of Hair Restoration Surgery consensus notes that at least 12 months of treatment is needed before concluding finasteride is or is not effective for female-pattern hair loss.

Patient Counseling Points: What to Tell Your Prescriber (and What to Ask)

Most women are not warned explicitly about the androgen-pathway overlap between these two drugs because it rarely causes acute harm. These are the questions worth raising at your appointment:

• "My baseline testosterone is [X]. Should we recheck it after I start finasteride?"
• "If I decide I want to get pregnant, exactly how long should I wait after stopping finasteride before removing the IUD?"
• "Are there signs that the finasteride is suppressing androgens too aggressively given I also have a levonorgestrel IUD?"
• "My IUD was inserted [X] months ago. Are the levonorgestrel levels at the point where systemic androgenic exposure is lower?"

The last question matters because levonorgestrel release rates from the 52-mg Mirena start at approximately 20 micrograms per day and fall to approximately 8 micrograms per day by year five. Earlier in the IUD's life, systemic androgenic exposure from levonorgestrel is higher.

A Note on Off-Label Finasteride Use in Women

Finasteride is FDA-approved only in men. Its use in women is entirely off-label in the United States. This does not mean it is inappropriate. A 2020 systematic review in JAMA Dermatology found evidence supporting finasteride's efficacy for female androgenic alopecia, with most trials showing statistically significant improvements in hair density compared with placebo. The practice is common in academic dermatology and reproductive endocrinology. Women deserve a candid conversation from their prescriber about the off-label status, the evidence base, the teratogenicity risk, and the monitoring plan before starting.